Related Experiment Videos
Practical considerations for switching beta-blockers in heart failure patients
William T Abraham1, Srinivas Iyengar
1Division of Cardiovascular Medicine, Davis Heart & Lung Research Institute, Ohio State University Heart Center, Columbus, Ohio, USA.
Reviews in Cardiovascular Medicine
|June 9, 2004
Summary
Beta-blockers vary in effectiveness for heart failure (HF). Clinicians must choose the best beta-blocker based on individual patient needs and drug properties for optimal outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blocker therapy is vital for hypertension, myocardial infarction, and heart failure (HF).
- Significant variations exist in beta-blocker efficacy and outcomes, especially in HF treatment.
- Individual beta-blockers differ in pharmacology, receptor interactions, hemodynamics, and tolerability.
Purpose of the Study:
- To highlight the differences among beta-blocker agents.
- To provide protocols for safely switching between specific beta-blockers.
- To guide clinicians in selecting optimal beta-blocker therapy for heart failure.
Main Methods:
- Review of clinical evidence on beta-blocker efficacy in HF.
- Development of two protocols for switching therapy between carvedilol and beta1-selective agents.
- Focus on receptor blockade subtype and intrinsic drug effects.
Main Results:
- Beta-blockers are not a homogeneous class; individual agents have distinct properties.
- Safe and tolerable protocols for switching between carvedilol and beta1-selective agents are presented.
- Optimizing beta-blocker selection can improve HF management.
Conclusions:
- Choosing the appropriate beta-blocker is crucial for effective heart failure management.
- Understanding specific drug pharmacology and receptor interactions aids in treatment selection.
- Physicians should utilize adrenergic blocking agents that offer optimal therapy with minimal adverse effects.